On the stock market since 2020, it operates in the world of health and science. It has 24 employees. Now — the numbers.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 12 months, executives reported 125 sells against just 27 buys. Not an alarm bell by itself, but a number worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, GMTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GMTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.